Panbela Therapeutics (PBLA) Short Interest Ratio & Short Volume

Short interest is the volume of Panbela Therapeutics shares that have been sold short but have not yet been closed out or covered. As of February 29th, investors have sold 114,700 shares of PBLA short. 2.36% of Panbela Therapeutics' shares are currently sold short. Learn More on Panbela Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.36% of Panbela Therapeutics' floating shares are currently sold short.

Panbela Therapeutics saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 114,700 shares, an increase of 7.2% from the previous total of 107,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Panbela Therapeutics currently has issued a total of 3,480,000 shares. Some of Panbela Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Panbela Therapeutics currently has a public float of 4,850,000 shares.

2.36% of Panbela Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Panbela Therapeutics: GRI Bio, Inc. (0.61%), NeuBase Therapeutics, Inc. (0.81%), 180 Life Sciences Corp. (3.30%), InMed Pharmaceuticals Inc. (1.89%), Comera Life Sciences Holdings, Inc. (2.38%), Sunshine Biopharma, Inc. (7.32%), PainReform Ltd. (2.95%), Galmed Pharmaceuticals Ltd. (2.21%), Bio-Path Holdings, Inc. (3.64%), Lucy Scientific Discovery Inc. (1.69%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks.

Short selling PBLA is an investing strategy that aims to generate trading profit from Panbela Therapeutics as its price is falling. PBLA shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Panbela Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PBLA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PBLA, twice per month. The most recent reporting period available is February, 29 2024.